Background {#Sec1}
==========

Primary spinal osseous tumors are uncommon; previous reports showed that spinal osseous tumors were comprising 6 \~ 10% of all bone tumors \[[@CR1]--[@CR5]\]. Little was known about the etiology of spine osseous tumors. Published case reports focused on spine neoplasm usually had a limited case number, and few reports described epidemiological characteristics of spine osseous tumors. However, it is important to understand the etiology of spinal osseous tumors and information regarding the epidemiology of primary spine osseous tumors.

The present study performed an epidemiological analysis of 1209 consecutive tumors of osseous spine registered in 3 collaborating state bone tumor database (Eastern China) between 1995 and 2015. To our knowledge, the present study is the first report of epidemiological data concerning spinal osseous tumors in Asian population. Our findings showed that epidemiological features of primary spinal osseous tumors in xanthoderm, with respect to relative frequency and distribution of the various histologic types, as well as the clinical data, and compare the results with other epidemiological findings from different geographic locations around the world, which could provide valuable clues for epidemiology of primary spine osseous tumors in Asian.

Methods {#Sec2}
=======

Data sources {#Sec3}
------------

Data for this study were obtained from Bone Tumors and Nervous System Tumors Biobank of Shanghai (BT&NSTBS), Bone Tumor Sample Databases and Digital Information Platform of Shanghai (BTSD&DIPS), and Shanghai Biobank Network of Common Human Tumor Tissue (SBNCHTT). One thousand two hundred nine cases of spinal osseous tumors registered in abovementioned 3 database between 1995 and 2015 were selected for this study. Data collected for each patient included personal information such as name, age, sex, anatomical site of the tumor, and clinical and histological diagnoses. In the case of recurrent tumors, the histological appearance of the original and the recurrent tumors was compared and was considered as only one case. The diagnoses were re-evaluated according to the criteria suggested for the 2013 WHO histological classification \[[@CR6]\].

Statistics {#Sec4}
----------

SPSS17.0 software (SPSS Inc., Chicago, IL) was used for statistical analysis of experimental data. Descriptive statistics was performed to calculate the frequency and percentages of variables mentioned before. Age was stratified into various groups at 10-year intervals.

Results {#Sec5}
=======

The histological types of the spinal osseous tumors are listed in Table [1](#Tab1){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}. Of these, 64.5% (780 cases) were benign and 35.5% (429 cases) were malignant, The most common histological type of benign tumors was hemangioma accounting for 28.1% of all tumors (340 cases), followed by giant cell tumor (15.7%; 190 cases), osteoblastoma (4.4%; 53 cases), aneurysmal bone cyst (2.9%; 35 cases), eosinophilic granuloma (3.9%; 47 cases), osteochondroma (3.8%; 46 cases), solitary bone cyst (2.1%; 25 cases), osteoid osteoma (1.4%; 17 cases), fibroma (1.3%; 16 cases), lipoma (0.6%; 7 cases), and fibrous dysplasia (0.3%; 4 cases). Of malignant tumors, chordoma was the most common malignant tumor (9.8% of all tumors, 119 cases), followed by plasma cell myeloma multiple myeloma (8.5%,103 cases), chondrosarcoma (5.2%, 63 cases), malignant lymphoma (4.5%; 54 cases), malignant neurilemmoma (2.5%; 30 cases), primitive neural ectodermal tumor (PNET)\\Ewing's sarcoma (1.4%; 17 cases), malignant fibrous histiocytoma (1.3%; 16 cases), osteosarcoma (1.1%; 13 cases), and other sarcomas such as angiosarcoma, fibrosarcoma, liposarcoma, and leiomyosarcoma (less than 1%).Table 1Frequency, age, and gender distribution of primary spine osseous tumorsType of tumorNumber (%)MaleFemaleMale vs femaleAge range (years)Mean ± SD (age)No.%^a^No.%^a^No.%^a^MaleFemaleTotalBenign tumors78064.540933.837130.752.4 vs 47.6%9--7933.7 ± 19.235.9 ± 20.634.7 ± 19.8Hemangioma34028.117414.416613.751.2 vs 48.8%12--7947.1 ± 14.351.5 ± 12.949.2 ± 13.7Giant cell tumor19015.7917.5998.247.9 vs 52.1%15--6634.5 ± 11.032.9 ± 12.133.6 ± 11.5Eosinophililc granuloma473.9363.0110.976.6 vs 23.4%10--5623.7 ± 14.329 ± 17.623.7 ± 14.7Osteoblastoma534.4282.3252.152.8 vs 47.2%9--5432.6 ± 10.526.5 ± 15.028.7 ± 13.2Fibroma161.3100.860.562.5 vs 37.5%26--7641.6 ± 18.250.5 ± 15.044.9 ± 17.1Osteoid osteoma171.480.790.747.1 vs 52.9%16--6731.2 ± 22.339.0 ± 16.834.6 ± 19.8Osteochondroma463.8282.3181.560.9 vs 39.1%13--6434.0 ± 16.638.7 ± 20.836.1 ± 18.4Solitary bone cyst252.180.7171.432.0 vs 68.0%15--6429.5 ± 15.248.8 ± 11.941.1 ± 16.2Lipoma70.650.420.271.4 vs 28.6%23--6341.8 ± 16.531.0 ± 11.338.7 ± 15.2Aneurysmal bone cyst352.9191.6161.354.3 vs 45.7%10--6225 ± 12.536.4 ± 15.330.4 ± 14.8Fibrous dysplasia40.320.220.250.0 vs 50.0%25--3229.5 ± 3.527 ± 2.828.3 ± 3.0Malignant tumors42935.528623.714311.866.7 vs 33.3%8--8148.3 ± 16.746.3 ± 16.347.4 ± 16.5PNET/ Ewing's sarcoma171.490.780.752.9 vs 47.1%11--4626 ± 13.325.8 ± 7.925.9 ± 10.9Chordoma1199.8796.5403.366.4 vs 33.6%27--8156.6 ± 15.053.3 ± 13.355.5 ± 14.1Malignant fibrous histiocytoma161.3110.950.468.8 vs 31.2%29--6751 ± 14.550.7 ± 1.950.9 ± 11.3Liposarcoma10.010.000.0NA4444NA44Osteosarcoma131.150.480.738.5 vs 61.5%14--6040.2 ± 21.025.8 ± 11.733.6 ± 18.2Angiosarcoma100.870.630.270.0 vs 30.0%36--7354.3 ± 11.345.0 ± 7.851.5 ± 10.9Malignant neurilemmoma302.5151.2151.250.0 vs 50.0%8--7140.4 ± 16.350.3 ± 12.145.3 ± 15.0Plasma cell myeloma1038.5756.2282.372.8 vs 27.2%10--7649.8 ± 15.357.2 ± 12.652.0 ± 14.8Malignant lymphoma544.5302.5242.055.6 vs 44.4%10--7747.2 ± 21.046.5 ± 18.746.9 ± 19.6Leiomyosarcoma10.010.000.0NA5555NA55Chondrosarcoma635.2524.3110.982.5 vs 17.5%20--6846.1 ± 14.537.3 ± 14.844.0 ± 14.7Fibrosarcoma20.210.010.050.0 vs 50.0%30--61613045.5 ± 21.9Total120910069557.551442.557.5 vs 42.5%8--8139.1 ± 16.939.6 ± 16.739.3 ± 16.8*NA* not applicable^a^% in all tumors Fig. 1Distribution of primary spine osseous tumors. Distribution of **a** all primary spine osseous tumor, **b** benign spine osseous, and **c** malignant spine osseous tumor cases by histological type

Of the benign tumors, 20.5% were situated in the cervical spine, 26.1% in the thoracic spine, 12.0% in the lumbar spine, and 5.4% in the sacral spine. Of the malignant tumors, 6.9% were situated in the cervical spine, 12.0% in the thoracic spine, 6.3% in the lumbar spine, and 10.7% in the sacral spine. Of all tumors, 27.4% were situated in the cervical spine, 38.1% in the thoracic spine, 18.4% in the lumbar spine, and 16.1% in the sacral spine (Table [2](#Tab2){ref-type="table"}).Table 2Distribution of spine osseous tumors by locationType of tumorCervical spineThoracic spineLumbar spineSacral spineTotalsNo.%No.%No.%No.%No.%Benign tumors25720.532826.115112.0685.4804(780)^a^64.0Hemangioma1048.314911.7866.8110.9350(340)^a^27.9Giant cell tumor443.5876.9231.8362.919015.1Eosinophililc granuoma201.6221.650.400.0473.7Osteoblastoma171.4302.450.410.0534.2Fibroma171.450.450.430.230(16)2.4Osteoid osteoma121.020.230.200.0171.4Osteochondroma211.7121.0110.920.2463.7Solitary bone cyst80.620.250.4100.8252.0Lipoma50.410.000.010.070.6Aneurysmal bone cyst90.7161.360.540.3352.8Fibrous dysplasia00.020.220.200.040.3Malignant tumors876.915112.0806.313410.7452(429) ^a^36.0PNET/Ewing's sarcoma10.040.390.730.2171.4Chordoma292.350.450.4806.41199.5Malignant fibrous histiocytoma00.080.630.250.4161.3Liposarcoma00.000.000.010.010.0Osteosarcoma20.260.600.050.4131.0Angiosarcoma10.0121.040.300.017(10)1.4Malignant neurilemmoma40.340.3121.0121.032(30) ^a^2.5Plasma cell myeloma272.1504.0262.190.7112(103)8.9Leiomyosarcoma00.000.000.010.010.0Malignant lymphoma90.7262.1181.460.559(54)^a^4.7Chondrosarcoma141.1362.920.2110.9635.0Fibrosarcoma00.000.010.010.020.2Total34427.447938.123118.420216.11256(1209) ^a^100^a^More than two anatomical position involved in the same patient

In our series, most tumors with different histological types showed a similar distribution in males and females, although chordoma (119 cases, M:F = 2:1), plasma cell myeloma (103 cases, M:F = 2.7:1), chondrosarcoma (63 cases, M:F = 4.7:1), and eosinophilic granuoma (47 cases, M:F = 3.3:1) affected more frequently males than females (Table [3](#Tab3){ref-type="table"}). From a total of 1209 bone tumors, the mean age (mean ± SD) was 39.3 ± 16.8 years (range, 8--81 years), 57.5% (695 cases) of the tumors occurred in males and 42.5% (514cases) in females, with a mean age (mean ± SD) of 39.1 ± 16.9 and 39.6 ± 16.7 years. The mean age (mean ± SD) of benign tumors group was 34.7 ± 19.8 years (range, 9--79 years). Of 780 benign tumors, 409 cases (33.8% of all cases) occurred in males and 371 cases (30.7% of all cases) in females (M:F = 1.1:1), with a mean age (mean ± SD) of 33.7 ± 19.2 and 35.9 ± 20.6 years. The mean age (mean ± SD) of malignant tumors group was 47.4 ± 16.5 years (range, 8--81 years). Of 429 malignant tumors, 286 cases (23.7% of all cases) occurred in males and 143 cases (11.8% of all cases) in females, with a mean age (mean ± SD) of 48.3 ± 16.7 and 46.3 ± 16.3 years. The most commonly affected age group for benign tumors was the 31- to 40-year-old group (14.3%; 173 cases), followed by the 51- to 60-year-old group (11.4%; 138 cases), and by the 41- to 50-year-old group (11.2%; 136 cases). The most common age group affected by malignant bone tumors was the 41- to 50-year-old group (7.9%; 95cases), followed by the 61- to 70-year-old group (6.8%; 82 cases). A similar frequency was observed in the 31- to 40-year-old group (6.7%; 81cases) and the 51- to 60-year-old group (6.5%; 79 cases).Table 3Age distribution of patients with primary spine osseous tumors (years)Type of tumor0--1011--2021--3031--4041--5051--6061--7071--8081--90Total no. (%)No. (%)No. (%)No. (%)No. (%)No. (%)No. (%)No. (%)No. (%)No. (%)Benign tumors14(1.2%)102(8.4%)122(10.1%)173(14.3%)136(11.2%)138(11.4%)76(6.3%)19(1.6%)0(0.0%)780(64.5%)Hemangioma1(0.0%)14(1.2%)18(1.5%)62(5.1%)78(6.5%)96(7.9%)53(4.4%)18(1.5%)0(0.0%)340(28.1%)Giant cell tumor0(0.0%)27(2.2%)50(4.1%)62(5.1%)32(2.6%)11(0.9%)8(0.7%)0(0.0%)0(0.0%)190(15.7%)Eosinophililc granuloma3(0.2%)23(1.9%)9(0.7%)5(0.4%)2(0.2%)5(0.4%)0(0.0%)0(0.0%)0(0.0%)47(3.9%)Osteoblastoma6(0.5%)11(0.9%)14(1.2%)11(0.9%)5(0.4%)6(0.5%)0(0.0%)0(0.0%)0(0.0%)53(4.4%)Fibroma0(0.0%)0(0.0%)4(0.3%)4(0.3%)2(0.2%)2(0.2%)3(0.2%)1(0.0%)0(0.0%)16(1.3%)Osteoid osteoma0(0.0%)5(0.4%)3(0.2%)2(0.2%)2(0.2%)3(0.2%)2(0.2%)0(0.0%)0(0.0%)17(1.4%)Osteochondroma2(0.2%)12(1.0%)8(0.7%)9(0.7%)5(0.4%)5(0.4%)5(0.4%)0(0.0%)0(0.0%)46(3.8%)Solitary bone cyst0(0.0%)2(0.2%)3(0.2%)5(0.4%)6(0.5%)6(0.5%)3(0.2%)0(0.0%)0(0.0%)25(2.1%)Lipoma0(0.0%)0(0.0%)2(0.2%)3(0.2%)1(0.0%)1(0.0%)0(0.0%)0(0.0%)0(0.0%)7(0.6%)Aneurysmal bone cyst2(0.2%)8(0.7%)9(0.7%)8(0.7%)3(0.2%)3(0.2%)2(0.2%)0(0.0%)0(0.0%)35(2.9%)Fibrous dysplasia0(0.0%)0(0.0%)2(0.2%)2(0.2%)0(0.0%)0(0.0%)0(0.0%)0(0.0%)0(0.0%)4(0.3%)Malignant tumors5(0.4%)17(1.4%)36(3.0%)81(6.7%)95(7.9%)79(6.5%)82(6.8%)32(2.6%)2(0.2%)429(35.5%)PNET/Ewing's sarcoma0(0.0%)5(0.4%)7(0.6%)3(0.2%)2(0.2%)0(0.0%)0(0.0%)0(0.0%)0(0.0%)17(1.4%)Chordoma0(0.0%)0(0.0%)3(0.2%)17(1.4%)27(2.2%)23(1.9%)32(2.6%)15(1.2%)2(0.2%)119(9.8%)Malignant fibrous histiocytoma0(0.0%)0(0.0%)2(0.2%)0(0.0%)5(0.4%)6(0.5%)3(0.2%)0(0.0%)0(0.0%)16(1.3%)Liposarcoma0(0.0%)0(0.0%)0(0.0%)0(0.0%)1(0.0%)0(0.0%)0(0.0%)0(0.0%)0(0.0%)1(0.0%)Osteosarcoma0(0.0%)6(0.5%)2(0.2%)0(0.0%)3(0.2%)2(0.2%)0(0.0%)0(0.0%)0(0.0%)13(1.1%)Angiosarcoma0(0.0%)0(0.0%)0(0.0%)2(0.2%)3(0.2%)3(0.2%)1(0.0%)1(0.0%)0(0.0%)10(0.8%)Malignant neurilemmoma1(0.0%)1(0.0%)1(0.0%)9(0.7%)8(0.7%)5(0.4%)4(0.3%)1(0.0%)0(0.0%)30(2.5%)Plasma cell myeloma2(0.2%)0(0.0%)3(0.2%)17(1.4%)26(2.2%)22(1.8%)24(2.0%)9(0.7%)0(0.0%)103(8.5%)Leiomyosarcoma0(0.0%)0(0.0%)0(0.0%)0(0.0%)0(0.0%)1(0.0%)0(0.0%)0(0.0%)0(0.0%)1(0.0%)Malignant lymphoma2(0.2%)3(0.2%)6(0.5%)9(0.7%)12(1.0%)8(0.7%)8(0.7%)6(0.5%)0(0.0%)54(4.5%)Chondrosarcoma0(0.0%)2(0.2%)11(0.9%)24(2.0%)8(0.7%)9(0.7%)9(0.7%)0(0.0%)0(0.0%)63(5.2%)Fibrosarcoma0(0.0%)0(0.0%)1(0.0%)0(0.0%)0(0.0%)0(0.0%)1(0.0%)0(0.0%)0(0.0%)2(0.2%)Total19(1.6%)119(9.8%)158(13.1%)254(21.0%)231(19.1%)217(17.9%)158(13.1%)51(4.2%)2(0.2%)1209(100%)

As the most common presenting symptom, pain was found in 54.4% (658/1209) of patients, affecting 35.0% (273/780) of the benign and 89.7% (385/429) of the malignant tumors. Mass (swelling) was seen in 4.0% (31/780) of benign tumors and 8.9% (38/429) of malignant tumors. One hundred fifty-six patients (12.9%) had the symptoms of radiculopathy. Of all cases, 9.2% (111/1209) of patients had signs of subtotal or complete cord compression. The cord compression symptoms included motor weakness (8.2%, 99/1209), sphincter dysfunction (0.7%, 8/1209), and paraplegia (0.3%, 4/1209). Pathological fracture was found in 4.7% (57/1209) of patients. Other symptoms included deformity (2.1%, 25/1209) and weight loss (1.9%, 23/1209) (Table [4](#Tab4){ref-type="table"}).Table 4First presenting features when diagnosed with primary spine osseous tumorsTotal no. of casePainMass (swelling)RadiculopathyMotor weaknessSphincter dysfunctionParaplegiaPathological fractureDeformityWeight lossBenign tumors780273(35.0%)31(4.0%)72(9.2%)45(5.8%)0023(2.9%)4(0.5%)7(0.9%)Hemangioma3401821000001Giant cell tumor190169116543002132Eosinophililc granuloma4735174100001Osteoblastoma53200000000Fibroma16400000000Osteoid osteoma17300000001Osteochondroma461300000001Solitary bone cyst25210000000Lipoma7000000000Aneurysmal bone cyst352501100101Fibrous dysplasia4201000110Malignant tumors429385(89.7%)38(8.9%)84(19.9%)54(12.6%)8(1.9%)4(0.9%)34(7.9%)21(4.9%)16(3.7%)PNET/Ewing's sarcoma171610000100Chordoma119101154335721263Malignant\
fibrous histiocytoma1613100000100Liposarcoma1101000100Osteosarcoma13132000000Angiosarcoma10911000000Malignant neurilemmoma30280281510000Plasma cell myeloma1039207222191513Leiomyosarcoma545173100000Malignant lymphoma1100000000Chondrosarcoma635800000000Fibrosarcoma2221100000Total1209658(54.4%)69(5.7%)156(12.9%)99(8.2%)8(0.7%)4(0.3%)57(4.7%)25(2.1%)23(1.9%)

In our series, 398 cases with malignant tumors and 187 cases with benign tumors undergone surgery. Two hundred seventy-one cases with malignancies received chemotherapy. Thirty-four cases with malignant tumors were given radiotherapy. And other treatments were performed to 6 malignant cases and 35 benign cases respectively (Additional file [1](#MOESM1){ref-type="media"}: Table S1).

Discussion {#Sec6}
==========

Primary bone tumors of the spine are representing only less than 10% of all bone neoplasms. Available reports on the epidemiologic features of primary osseous spine tumors were mostly among Americans and Europeans \[[@CR7]--[@CR11]\]. To our knowledge, the present report represents epidemiologic features based the largest series of spinal osseous tumors from Asian. However, there are some differences of epidemiological characteristics in our study and previous reports (Table [5](#Tab5){ref-type="table"}) \[[@CR8], [@CR10]\]. In Kelley's series \[[@CR10]\], 23.02% tumors were benign and 76.98% tumors were malignant, plasma cell myeloma was the most common primary malignant tumor, accounting for 26%, followed by chordoma (22.22%) and osteosarcoma (9.52%). Osteoblastoma (5.56%) was the most common benign tumor, followed osteoclastoma (0.79%) and aneurysmal bone cyst (0.79%). In our series, benign tumors comprised 64.5% of primary tumors. The most frequent benign was hemangioma (28.1%), followed by giant cell tumor (15.7%) and osteoblastoma (4.4%). The most frequent malignant was chordoma (9.8%), followed by plasma cell myeloma (8.5%) and chondrosarcoma (5.2%). These findings were not consistent with results from previous studies based in Caucasian, which would be influenced by geographical and racial variations in different reports.Table 5World literature of population-based studies on the epidemiology of primary spine osseous tumorThis studySimon P. KelleyS. BorianiAuthor's countryChinaUKItalyYear of publication201620071995Period of study1995--2015 (20 years)1958--2000 (42 years)1946--1992 (46 years)No. of cases1209127366GenderMale: 695 Female:514Male: 66 Female:61Not reportedPredominant presenting symptomPainPainNot reportedPercentage of benign tumors64.5%22.8%56.8%Percentage of malignant tumors35.5%77.2%43.2%Most common type of benign tumorsHemangiomaOsteoblastoma (7/127)Eosinophilic granulomaMost common type of malignant tumorsChordomaPlasma cell myelomaPlasma cell myelomaMost common segment of spine affectedThoracic spine (479/1256)^a^Thoracic spine (48/127)Lumbar spine (181/366)Mean age at presentation (range)39.3 ± 16.8 (range 8--81 years)42 (range 7--76 years)Not reported^a^More than two anatomical position involved in the same patient

As the most frequent benign primary spine osseous tumor in present study, hemangioma was accounting for approximately one third of all primary tumors. During the past 20 years (1995--2015), 340 (28.1% of all cases) cases of spinal hemangioma were diagnosed, and 350 vertebrae were involved. This incidence of spinal hemangioma was significantly higher than that in other country \[[@CR12]\], which suggested different epidemiologic features of spinal hemangioma in Asians. Giant cell tumor (GCT) of bone was considered a benign osteolytic tumor with variable aggressiveness and accounted for approximately 5% of all bone tumors \[[@CR4], [@CR13], [@CR14]\]. In our study, GCTs accounted for 15.7% of spine osseous lesions, this incidence was markedly higher than that reported in other studies \[[@CR15]--[@CR19]\]. Almost of GCTs occurred in the second to fourth decades, with a slight female predilection (M:F = 1:1.1) in the present series. The female predilection of GCT is supported by the earlier reports \[[@CR17], [@CR20]--[@CR22]\]. Furthermore, GCTs also showed predilection for the thoracic vertebra of spine in our study, which is not in accordance with other reports \[[@CR19], [@CR23]\]. Osteoblastoma was the third most common benign tumor in our study, with a relative frequency of 4.4% which was higher compared with the previous report \[[@CR24]\]. In Herman M. Kroon's and Richard A. Mcleod's reports \[[@CR25], [@CR26]\], osteoblastoma obviously affected more males than females (64:34 and 87:36 respectively). In our study, we only observed a slight male predilection (M:F = 1:1.1). The most involved location was the thoracic spine, which is consistent with those reported from Europe and America \[[@CR27], [@CR28]\].

Chordoma was the most common malignant tumor which occurred more in males than in females in the present study. We found a significant predilection for males (M:F = 79:40), in agreement with reports by S Boriani (M:F = 37:15) \[[@CR29]\], Silvia Stacchiotti (M:F = 91:47) \[[@CR30]\], and Johannm Bjornsson (M:F = 27:13) \[[@CR31]\]. It is worth noting that female preponderance (17:22) of chordoma was reported in Sweden \[[@CR32]\]. In our series, chordomas were typically seen in adults and elderly, tended to occur in the sacrum (9.5%, 119 cases), which is consistent with the previous reports. In the present study, plasma cell myeloma accounted for 8.5% (103 cases) of all cases, representing the second most frequent primary malignant osseous tumor of spine, and often occurring in thoracic spine (4.0%, 50 vertebrae were involved). All plasma cell myeloma cases were found in the 4th--7th decade of life with a male predominance (M:F = 2.7:1). Previous studies reported that chondrosarcoma accounted for 3--12% of all spine primary tumors \[[@CR33]--[@CR36]\]. In S Boriani's report, the lumbar spine was the most frequently involved location (15/22, 68%) \[[@CR33]\]. However, in the present study, thoracic spine was the most common location involved with chondrosarcoma (2.9%, 36 cases), and only 2 cases were observed in the lumbar spine. Most patients commonly encountered chondrosarcoma after the age of 20, with a great male predilection (M:F = 4.7:1).

Surgery is the first choice for the pain and neurological symptoms caused by spine tumors. Surgery can completely or partly alleviate tumor compression to the spinal cord, establish a tumor-free solid spine and relieve pain. In primary malignant tumors of the spine, total/partial laminectomy, total/partial vertebral body resection, and piecemeal resection and curettage, in addition to the surgical procedures described above, can be used. Chemotherapy and radiotherapy after surgery were used to reduce the risk of the cancer relapse or shrinks some malignant tumor such Ewing's sarcoma that cannot be completely removed with surgery. Many benign silent (no symptom) tumors such as hemangioma were found in health checkup, and most of them did not receive any treatment. Although the WHO defines GCT as a benign osteolytic neoplasm, GCT displays the characteristics of both malignant and benign tumors and actually represents a benign tumor with the potential of malignancy \[[@CR37]--[@CR39]\]. In our series, most cases of GCT undergone total spondylectomy, vertebrectomy, piecemeal resection or curettage. Some cases of GCT received other therapy such as bisphosphonate treatment after surgery.

Conclusions {#Sec7}
===========

Our study results represent data on the epidemiology of spinal osseous tumors in a large population of patients. We think that these data may reflect the epidemiological features of spine osseous tumors in Eastern China. For geographical and racial variations, the incidence of these neoplasms in a developing country is partly different from that found in other countries. There were several limitations in this study. As medical imaging technology have improved greatly during the study time span, the diagnosis sensitivity of primary spinal osseous tumors should lead to different prevalence in different time. Although the prognosis of spinal osseous tumors and longitudinal changes could not be fully assessed due to the nature of a retrospective study, we hope our work could provide useful epidemiological information as these data may have important implications for public health programs.
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